Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 152.00
0.00 (0.00%)
At close: Mar 6, 2026
Noile-Immune Biotech Revenue
In the year 2025, Noile-Immune Biotech had annual revenue of 5.00M JPY, down -28.57%.
Revenue
5.00M
Revenue Growth
-28.57%
P/S Ratio
1,316.37
Revenue / Employee
200.00K
Employees
25
Market Cap
6.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | -2.00M | -28.57% |
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Linical | 9.32B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| CellSource | 3.71B |
| OncoTherapy Science | 784.00M |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |